Kansuinine A and Kansuinine B from Euphorbia kansui L. Inhibit IL-6-induced Stat3 Activation

Abstract

The current study was performed to examine the mechanisms underlying the potential effects of E. kansui on IL-6-induced cellular signaling in human hepatoma cells. We found that two diterpenoids, kansuinine A and B, from E. kansui have an inhibitory effect on IL-6-induced Stat3 activation by activating ERK1/2. Inhibition of MEK significantly blocked the effects of kansuinine A and B on IL-6-induced Stat3 activation and tyrosine phosphorylation. These results suggest that blocking of IL-6-induced signal transduction is partially due to the sustained activation of ERK1/2 by kansuinine A and B, which in turn results in an increase of Stat3 serine phosphorylation and SOCS-3 expression. Treatment with kansuinine A and B represents a novel method to block these IL-6-induced effects.

Key words

Euphorbia kansui Liou - Euphorbiaceae - kansuinine A - kansuinine B - IL‐6 - Stat3 - ERK1/2

References

• 1 Strassmann G, Masui Y, Chizzonite R, Fong M. Mechanisms of experimental cancer cachexia. Local involvement of IL-1 in colon 26 tumor.  J Immunol. 1993;  150 2341-2345
• 2 Luger T A, Schwarz T, Krutmann J, Kirnbauer R, Neuner P, Kock A, Urbanski A, Borth W, Schauer E. Interleukin-6 is produced by epidermal cells and plays an important role in the activation of human T-lymphocytes and natural killer cells.  Ann NY Acad Sci. 2008;  557 405-414
• 3 Neveu W A, Allard J B, Dienz O, Wargo M J, Ciliberto G, Whittaker L A, Rincon M. IL-6 is required for airway mucus production induced by inhaled fungal allergens.  J Immunol. 2009;  183 1732-1738
• 4 Barton B E. IL-6-like cytokines and cancer cachexia: consequences of chronic inflammation.  Immunol Res. 2001;  23 41-58
• 5 Morishima A, Marui A, Shimamoto T, Saji Y, Nishina T, Komeda M. A case of interleukin-6-producing cardiac myxoma resembling multicentric Castleman's disease.  J Thorac Cardiovasc Surg. 2009;  138 499-501
• 6 Nishimoto N, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Azuma J. Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis: evidence of safety and efficacy in a 5-year extension study.  Ann Rheum Dis. 2009;  68 1580-1584
• 7 Mori A, Toyoshima N, Saito M, Oka T, Irie T, Morioka M. Hypercalcemia and multiple osteolytic lesions associated with proinflammatory cytokines in a patient with acute lymphoblastic leukemia.  Rinsho Ketsueki. 2007;  48 559-564
• 8 Fulciniti M, Hideshima T, Vermot-Desroches C, Pozzi S, Nanjappa P, Shen Z, Patel N, Smith E S, Wang W, Prabhala R, Tai Y T, Tassone P, Anderson K C, Munshi N C. A high-affinity fully human anti-IL-6 mAb, 1339, for the treatment of multiple myeloma.  Clin Cancer Res. 2009;  15 7144-7152
• 9 Hayashi M, Rho M C, Enomoto A, Fukami A, Kim Y P, Kikuchi Y, Sunazuka T, Hirose T, Komiyama K, Omura S. Suppression of bone resorption by madindoline A, a novel nonpeptide antagonist to gp130.  Proc Natl Acad Sci USA. 2002;  99 14728-14733
• 10 Lütticken C, Wegenka U M, Yuan J, Buschmann J, Schindler C, Ziemiecki A, Harpur A G, Wilks A F, Yasukawa K, Taga T et al. Association of transcription factor APRF and protein kinase Jak1 with the interleukin-6 signal transducer gp130.  Science. 1994;  263 89-92
• 11 Ihle J N. STATs: signal transducers and activators of transcription.  Cell. 1996;  84 331-334
• 12 Sebt S M, Der C J. Opinion: searching for the elusive targets of farnesyltransferase inhibitors.  Nat Rev Cancer. 2003;  3 945-951
• 13 Darnell Jr J E. STATs and gene regulation.  Science. 1997;  277 1630-1635
• 14 Aaronson D S, Horvath C M. A road map for those who don't know JAK-STAT.  Science. 2003;  296 1653-1655
• 15 Sengupta T K, Talbot E S, Scherle P A, Ivashkiv L B. Rapid inhibition of interleukin-6 signaling and Stat3 activation mediated by mitogenactivated protein kinases.  Proc Natl Acad Sci USA. 1998;  95 1110-1112
• 16 Boulton T G, Nye S H, Robbins D J, Ip N Y, Radziejewska E, Morgenbesser S D, DePinho R A, Panayotatos N, Cobb M H, Yancopoulos G D. ERKs: a family of protein-serine/threonine kinases that are activated and tyrosine phosphorylated in response to insulin and NGF.  Cell. 1991;  65 663-675
• 17 Woodgett J R, Kyriakis J M, Avruch J, Zon L I, Zanke D J. Reconstitution of novel signalling cascades responding to cellular stresses.  Philos Trans R Soc Lond B Biol Sci. 1996;  351 135-141
• 18 Marshall C J. Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation.  Cell. 1995;  80 179-185
• 19 David M, Petricoin 3rd E, Benjamin C, Pine R, Weber M J, Larner A C. Requirement for MAP kinase (ERK2) activity in interferon alpha- and interferon beta-stimulated gene expression through STAT proteins.  Science. 1995;  22 1721-1723
• 20 Ihara S, Nakajima K, Fukada T, Hibi M, Nagata S, Hirano T, Fukui Y. Dual control of neurite outgrowth by STAT3 and MAP kinase in PC12 cells stimulated with interleukin-6.  EMBO J. 1997;  16 5345-5352
• 21 Boccaccio C, Andò M, Tamagnone L, Bardelli A, Michieli P, Battistini C, Comoglio P M. Induction of epithelial tubules by growth factor HGF depends on the STAT pathway.  Nature. 1998;  391 285-288
• 22 Alessi D R, Cuenda A, Cohen P, Dudley D T, Saltiel A R. PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo.  J Biol Chem. 1995;  270 27489-27494
• 23 Dudley D T, Pang L, Decker S J, Bridges A J, Saltiel A R. A synthetic inhibitor of the mitogen activated protein kinase cascade.  Proc Natl Acad Sci USA. 1995;  92 7686-7689
• 24 Wu T S, Lin Y M, Haruna M, Pan D J, Shingu T, Chen Y P, Hsu H Y. Antitumor agents, 119. Kansuiphorins A and B, two novel antileukemic diterpene esters from Euphorbia kansui.  J Nat Prod. 1991;  54 823-829
• 25 Yu F R, Lian X Z, Guo H Y, McGuire P M, Li R D, Wang R, Yu F H. Isolation and characterization of methyl esters and derivatives from Euphorbia kansui (Euphorbiaceae) and their inhibitory effects on the human SGC-7901 cells.  J Pharm Pharm Sci. 2005;  8 528-535
• 26 Yasukawa K, Akihisa T, Yoshida Z Y, Takido M. Inhibitory effect of euphol, a triterpene alcohol from the roots of Euphorbia kansui, on tumour promotion by 12-O-tetradecanoylphorbol-13-acetate in two-stage carcinogenesis in mouse skin.  J Pharm Pharmacol. 2000;  52 119-124
• 27 Zheng W F, Cui Z, Zhu Q. Cytotoxicity and antiviral activity of the compounds from Euphorbia kansui.  Planta Med. 1998;  64 754-756
• 28 Okouchi T, Abe T, Araki S, Arai S, Iida T, Wang L Y, Kitanaka S, Miyata S. Mechanism of proliferation arrest of embryonic cells of Xenopus by diterpene compounds.  Bioorg Med Chem. 2005;  13 3847-3851
• 29 Miyata S, Wang L Y, Wang N L, Yao X S, Kitanaka S. Selective inhibition of the growth of cancer cells by diterpenes selected with embryonic cells of Xenopus.  Cell Biol Int. 2004;  28 179-184
• 30 Miyata S, Wang L Y, Yoshida C, Kitanaka S. Inhibition of cellular proliferation by diterpenes, topoisomerase II inhibitor.  Bioorg Med Chem. 2006;  14 2048-2051
• 31 Pan Q, Min Z D. Studies on the structure of kansuinine A from Euphorbia kansui.  Chin Chem Lett. 2002;  13 1178-1180
• 32 Qin B, Perry L G, Broeckling C D, Du J, Stermitz F R, Paschke M W, Vivanco J M. Phytotoxic allelochemicals from roots and root exudates of leafy spurge (Euphorbia esula L.).  Plant Signal Behav. 2006;  1 323-327
• 33 Yan S F, Zou Y S, Gao Y, Zhai C, Mackman N, Lee S L, Milbrandt J, Pinsky D, Kisiel W, Stern D. Tissue factor transcription driven by Egr-1 is a critical mechanism of murine pulmonary fibrin deposition in hypoxia.  Proc Natl Acad Sci USA. 1998;  95 8298-8303
• 34 Tenhumberg S, Schuster B, Zhu L, Kovaleva M, Scheller J, Kallen K J, Rose-John S. gp130 Dimerization in the absence of ligand: preformed cytokine receptor complexes.  Biochem Biophys Res Commun. 2006;  346 649-657
• 35 Nicholas A C, David S, James A J. Tyrosine-phosphorylated SOCS-3 inhibits STAT activation but binds to p 120 RasGAP and activates Ras.  Nat Cell Biol. 2001;  3 460-465
• 36 Joanna B, Kshipra S, Dhammika N, Stephen O D, Agnes M R, Antonio E, Babu L K. A Survey of synthetic and natural phytotoxic compounds and phytoalexins as potential antimalarial compounds.  Biol Pharm Bull. 2007;  30 1740-1744
• 37 Wätjen W, Debbab A, Hohlfeld A, Chovolou Y, Kampkötter A, Edrada R A, Ebel R, Hakiki A, Mosaddak M, Totzke F, Kubbutat M H, Proksch P. Enniatins A1, B and B1 from an endophytic strain of Fusarium tricinctum induce apoptotic cell death in H4IIE hepatoma cells accompanied by inhibition of ERK phosphorylation.  Mol Nutr Food Res. 2009;  53 431-440
• 38 Aithal B K, Kumar M R, Rao B N, Udupa N, Rao B S. Juglone, a naphthoquinone from walnut, exerts cytotoxic and genotoxic effects against cultured melanoma tumor cells.  Cell Biol Int. 2009;  33 1039-1049
• 39 Lara T, Petros G, Johannes G B, Fred S, Peter C H, Lutz G. The inhibition of interleukin-6 dependent STAT activation by mitogen-activated protein kinases depends on tyrosine 759 in the cytoplasmic tail of glycoprotein 130.  J Biol Chem. 2000;  275 18810-18817
• 40 Kolaparthi V, Ahsan C, James W F. Farnesyl transferase inhibitor (R115777)-induced inhibition of STAT3 (Tyr705) phosphorylation in human pancreatic cancer cell lines require extracellular signal-regulated kinases.  Cancer Res. 2005;  65 2861-2871
• 41 Lee H K, Jung J, Lee S H, Seo S Y, Suh D J, Park H T. Extracellular signal-regulated kinase activation is required for serine 727 phosphorylation of STAT3 in Schwann cells in vitro and in vivo.  Kor J Physiol Pharmacol. 2009;  13 161-168
• 42 Chung J, Uchida E, Grammer T C, Blenis J. STAT3 serine phosphorylation by ERK-dependent and -independent pathways negatively modulates its tyrosine phosphorylation.  Mol Cell Biol. 1997;  17 6508-6516
• 43 Beadling C, Ng J, Babbage J W, Cantrell D A. Interleukin-2 activation of STAT5 requires the convergent action of tyrosine kinases and a serine/threonine kinase pathway distinct from the Raf1/ERK2 MAP kinase pathway.  EMBO J. 1996;  15 1902-1913
• 44 Narayana Y, Bansal K, Sinha A Y, Kapoor N, Puzo G, Gilleron M, Balaji K N. SOCS3 expression induced by PIM2 requires PKC and PI3K signaling.  Mol Immunol. 2009;  46 2947-2954
• 45 Yoshimura A, Naka T, Kubo M. SOCS proteins, cytokine signalling and immune regulation.  Nat Rev Immunol. 2007;  7 454-465
• 46 Huang K C, Chen C W, Chen J C, Lin W W. Statins induce suppressor of cytokine signaling-3 in macrophages.  FEBS Lett. 2003;  555 385-389

1 These authors equally contributed to this work.